← Back to the fund page Use your browser's print dialog and choose “Save as PDF”. A4, two pages.
InvestVerdict

Mahindra Manulife Large & Mid Cap Fund

Direct Plan · IDCW · Mid Cap · Scheme code 147841

Fund houseMahindra Manulife Mutual Fund
CategoryMid Cap
Plan & optionDirect · IDCW
History3.1 years

Returns (%)

 1M3M6M1Y3Y5Y7Y10YLaunch
This scheme 3.798.760.29 4.168.44 8.60
Nifty Midcap 150
benchmark
1.724.387.84 13.1317.93 18.43
Mid Cap
category median
10.2119.8417.23 17.08

Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published NAV history for this scheme.

Risk

 VolatilitySharpeSortinoBetaAlphaMax fall
This scheme 16.9% 0.11 0.15 0.87 -7.94% -24.3% 84.04
Nifty Midcap 150
benchmark
16.8%0.68 0.93 -21.0%

Risk-free rate 6.5%. Beta, alpha and R² are regressed on the 36 months this scheme and its benchmark share.

Growth of ₹100 since launch

9511112814420242026InvestVerdict

Drawdown from peak (%)

0%-9%-18%-27%20242026

Every one-year period it has lived through

WindowsWorstMedianBestPeriods that lost money
103 -12.3% -0.8% 38.1% 55%

Every one-year holding period in this scheme's history, not just the last one — the spread a real investor would have met depending only on when they started.

InvestVerdict

Mahindra Manulife Large & Mid Cap Fund

Direct Plan · IDCW

Allocation

By asset

Equity97.05%
Cash & Equivalents4.11%

By market cap

Concentration

Number of stocks70
Top 5 stocks15.99%
Top 10 stocks27.24%
Top 20 stocks44.92%
Largest holding4.64%
Largest sectorBanks 19.90%
Effective stocks59.0
Cash4.11%
InvestVerdict

Mahindra Manulife Large & Mid Cap Fund

Direct Plan · IDCW · holdings

Sector split

Banks — 19.9%Pharmaceuticals & Biotechnology — 11.5%Finance — 5.0%IT - Software — 4.5%Automobiles — 4.4%Cash & Equivalents — 4.1%Retailing — 3.9%Capital Markets — 3.8%Auto Components — 3.5%Other — 40.5%Banks19.9%Pharmaceuticals & Biotech…11.5%Finance5.0%IT - Software4.5%Automobiles4.4%Cash & Equivalents4.1%Retailing3.9%Capital Markets3.8%Auto Components3.5%Other40.5%
Banks19.90%
Pharmaceuticals & Biotechnology11.51%
Finance5.02%
IT - Software4.46%
Automobiles4.42%
Cash & Equivalents4.11%
Retailing3.94%
Capital Markets3.77%
Auto Components3.50%
Industrial Products3.33%

Not investment advice. InvestVerdict is not a SEBI-registered Investment Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past returns do not predict future ones. Generated 30 Aug 2026.